These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 17166187)

  • 21. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [National and European drug approval procedures].
    Mohrbutter KP
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):593-6. PubMed ID: 9527447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 24. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Draft EU regulation on paediatric medicines: some improvements but still far from perfect.
    Prescrire Int; 2006 Feb; 15(81):32-3. PubMed ID: 16548115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European paediatric research and children's therapeutic needs. A trial review.
    Pandolfini C; Bonati M
    Acta Paediatr; 2008 Sep; 97(9):1232-7. PubMed ID: 18489618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [European drug policy].
    Sauer F
    Bull Mem Acad R Med Belg; 1993; 148(5-6):207-12; discussion 212-6. PubMed ID: 8142930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Development of an anticancer drug in Japan based on a new clinical trial system].
    Nakashima H; Nakano S
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
    Bjerrum OJ
    Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EU law mandates drug testing in children.
    Sinha G
    J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
    Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Animal toxicology studies on new medicines and their relationship to clinical exposure: a review of international recommendations.
    Scales MD; Mahoney K
    Adverse Drug React Toxicol Rev; 1991; 10(3):155-68. PubMed ID: 1747442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug evaluation: new requirements and perspectives].
    Addis A; Rocchi F
    Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape.
    Benda N; Brandt A
    J Biopharm Stat; 2018; 28(1):3-9. PubMed ID: 29065277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.